Summary
The pharmacokinetics of xamoterol, a β-adrenergic partial agonist under clinical evaluation for the treatment of mild to moderate heart failure, have been studied in 8 cardiac failure patients (NYHA Class II) of mean age 62 years.
After i.v. dosing, the elimination half-life was 7.4±0.4 h, the total body clearance was 228±30 ml·min−1 and the volume of distribution at steady-state was 56±91. 72.5±4.3% of the dose was recovered unchanged in urine. After the oral dose, the absolute bioavailability of xamoterol was shown to be 5.9%. Peak plasma concentrations occurred 1 to 2.5 h after the oral dose. The apparent elimination half-life was significantly longer after oral doses (16±2 h) compared to that observed after an intravenous dose. Renal clearance of xamoterol exceeded glomerular filtration rate as measured by creatinine clearance.
The pharmacokinetics of xamoterol in cardiac failure patients with good renal function (creatinine clearance >90 ml·min−1) were similar to published data in young healthy male volunteers.
Similar content being viewed by others
References
Jennings G, Bobik A, Oddie C, Restall R (1984) Cardioselectivity, kinetics, haemodynamics and metabolic effects of xamoterol. Clin Pharmacol Ther 35: 594–603
Molajo AO, Bennett D (1985) Effect of xamoterol (ICI 118,587), a new β1-adrenoceptor partial agonist, on haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J 54: 17–21
Nuttall A, Snow HM (1982) The cardiovascular effects of ICI 118,587: A β1-adrenoceptor partial agonist. Br J Pharmacol 77: 381–388
Bastain W, Boyce MJ, Stafford LE, Morton PB, Clarke DA, Marlow HF (1988) Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. Eur J Clin Pharmacol 34: 469–473
Johnston A, Wollard RC (1983) Stripe: An interactive computer programme for the analysis of drug pharmacokinetics. J Pharmacol Methods 9: 193–199
Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York
Marten TR, Bourne GR, Miles GS, Shuker B, Rankine HD, Dutka VN (1984) The metabolism of ICI 118,587, a partial agonist of β1-adrenoceptors, in mice, rats, rabbits, dogs and humans. Drug Metab Dispos 12: 652–660
Marlow HF, Snow HM, Rouse W, Main BG (1982) ICI 118,587, a cardioselective beta-adrenoceptor partial agonist. Eur J Clin Invest 12: Abstract 49
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vigholt Sorensen, E., Faergeman, O., Day, M. et al. Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure. Eur J Clin Pharmacol 35, 183–185 (1988). https://doi.org/10.1007/BF00609250
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609250